|
|
|
 |
|
 |
Aerosolized AAT **
(Alpha-1 Antitrypsin) Collaboration partners
PARI, a Germany based world leader specializing in inhalation solutions
Indication
 |
Cystic Fibrosis (CF) |
Characteristics
Ready to use liquid for inhaled administration, 2% solution
Status
|
Phase II Clinical Trial has been successfuly completed (August 2008) |
|
Positive Phase II Data with Inhaled AAT in Cystic Fibrosis - the results demonstrate the product has an excellent safety profile and shows promising signs of efficacy, as Indicated by a reduction in lung iflammation (October/2008) |
Profile
The benefits of Kamada's high purity AAT for inhalation include:
|
Greater patient convenience |
|
Greater patient compliance |
|
Reduced treatment costs |
|
Larger treatment population |
|
Additional / new potential indications |
Kamada's Aerosolized AAT to treat CF was designated as an Orphan Drug by the FDA and EMEA
** Under development
|
|
|
|
|
More
|
